- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02548767
Adverse Metabolic Effects of Dietary Sugar
September 14, 2021 updated by: University of California, Davis
Adverse Metabolic Effects of Dietary Sugar: Ad Libitum vs Energy-balanced Diets
It is not known whether consumption of excessive amounts of sugar can increase risk factors for cardiovascular disease or diabetes in the absence of increased food (caloric) intake and weight gain, nor whether the negative effects of sugar consumption are made worse when accompanied by weight gain.
This study will investigate the effects of excess sugar when consumed with an energy-balanced diet that prevents weight gain, and the effects of excess sugar when consumed with a diet that can cause weight gain.
The results will determine whether excess sugar consumption and excess caloric intake that lead to weight gain have independent and additive effects on risk factors for cardiovascular disease or diabetes, and will have the potential to influence dietary guidelines and public health policy.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
Recent studies have demonstrated that consuming high fructose corn syrup (HFCS)- or sucrose-sweetened beverages increased lipid/lipoprotein risk factors for cardiovascular disease (CVD) in healthy adults compared with iso-caloric amounts of glucose or low-fat milk.
The longest of these studies, which utilized a 6-month intervention, also showed increased liver and muscle TG and increased visceral adipose deposition.
Neither of these studies found differences in weight gain between subjects consuming HFCS/sucrose beverages compared with control beverages.
These results suggest that it is not just excess calories and weight gain that mediate the effects of dietary sugar/fructose on the development of metabolic disease; rather, dietary sugar per se is also a contributor.
However, it is not known whether consumption of excessive amounts of sugar can increase risk factors for metabolic disease in the absence of positive energy balance and weight gain, nor whether the adverse effects of sugar consumption are exacerbated by weight gain.
This study will compare the contribution of sugar with the contribution of energy level to the increases in risk factors for metabolic disease induced by consumption of HFCS-sweetened beverages under energy-balanced or ad libitum conditions.
The investigators will measure risk factors and processes associated with metabolic disease in 4 groups of young, healthy adults who will consume 1) 0%, 2) or 25% of energy requirement as HFCS-sweetened beverages for 8 weeks with an energy-balanced diet for 6 weeks; 3) 0%, or 4) 25% of energy requirement as HFCS-sweetened beverages for 8 weeks with an ad libitum diet for 6 weeks.
All diets, formulated to achieve a comparable macronutrient intake (55% energy as carbohydrate, 35% fat, 15% protein) among all 4 experimental groups, will be provided to the subjects throughout the entire study.
The investigators hypothesize that under energy balanced (EB) condition that prevent body weight gain, consumption of HFCS-sweetened beverages will result in adverse metabolic effects compared with aspartame-sweetened beverages.
Consumption of HFCS-sweetened beverages with the ad libitum (AL) diet will result in increased energy intake and body weight gain compared with aspartame-sweetened beverages, and will also result in adverse metabolic effects that are more marked than with consumption of HFCS-sweetened beverages with the energy-balanced diet.
These results will demonstrate that consumption of HFCS-sweetened beverages increases risk for metabolic disease both directly, via the adverse effects of fructose on lipid and carbohydrate metabolism, and indirectly, via the effects of HFCS-sweetened beverages to promote excess energy intake and body weight gain.
These findings will have the potential to influence dietary guidelines and public health policy.
Study Type
Interventional
Enrollment (Actual)
36
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Davis, California, United States, 95616
- University of California, Davis
-
Sacramento, California, United States, 95655
- Clinical Research Center
-
Vallejo, California, United States, 94592
- Touro University California Translational Research Clinic and Student Health Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 40 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- BMI 22-28 kg/m2
- Self-reported stable body weight during the prior six months
Exclusion criteria:
- Fasting glucose >105 mg/dl
- Evidence of liver disorder [AST (Aspartate Aminotransferase) or ALT (Alanine Aminotransferase)] >200% upper limit of normal range)
- Evidence of kidney disorder (>2.0mg/dl creatinine)
- Evidence of thyroid disorder (out of normal range)
- Systolic blood pressure consistently over 140mm Hg (mercury) or diastolic blood pressure over 90mmHg
- Triglycerides > 200mg/dl
- LDL-C > 130mg/dl in combination with Chol:HDL > 4
- Hemoglobin < 8.5 g/dL
- Pregnant or lactating women
- Any other condition that, in the opinion of the investigators, would put the subject at risk
- Current, prior (within 12 months), or anticipated use of any hypolipidemic or anti-diabetic agents.
- Use of thyroid, anti-hypertensive, anti-depressant, weight loss medications or any other medication which, in the opinion of the investigator, may confound study results
- Use of tobacco
- Strenuous exerciser (>3.5 hours/week at a level more vigorous than walking)
- Surgery for weight loss
- Diet exclusions: Food allergies, special dietary restrictions, food allergies, routine consumption of less than 3 meals/day, routine ingestion of more than 2 sugar-sweetened beverages or 1 alcoholic beverage/day, unwillingness to consume any food on study menu
- Hydrogen concentration in breath sample following consumption of HFCS-beverage during screening >50ppm
- Veins that are assessed by the CCRC (Clinical Research Center) R.N.s as being unsuitable for long-term infusions and multiple blood draws from a catheter.
- Pre-existing claustrophobia or metal implants that preclude MRI
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HFCS-EB
Consume 3 servings/day of high fructose corn syrup (HFCS)-sweetened beverage along with the provided energy-balanced diet.
The 3 HFCS-sweetened beverages will contain 25% of energy requirement and the remainder of the provided diet will contain 75% of energy requirement.
All and only the provided beverage and diet will be consumed for eight weeks.
|
High fructose corn syrup provided as 15% HFCS/85% water (weight/weight) fruit-flavored beverage
Other Names:
Provided in quantities that equal energy requirement.
Formulated such that the overall macronutrient intake; including beverage; equal 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
Other Names:
|
Placebo Comparator: Asp-EB
Consume 3 servings/day of aspartame-sweetened beverage along with the provided energy-balanced diet.
The 3 aspartame-sweetened beverages will contain 0% of energy requirement and the remainder of the provided diet will contain 100% of energy requirement.
All and only the provided beverage and diet will be consumed for eight weeks.
|
Provided in quantities that equal energy requirement.
Formulated such that the overall macronutrient intake; including beverage; equal 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
Other Names:
Aspartame provided as 0.04% aspartame/99.96%
water (weight/weight), fruit-flavored beverage
Other Names:
|
Experimental: HFCS-AL
Consume 3 servings/day of high fructose corn syrup (HFCS)-sweetened beverage along with the provided ad libitum diet.
The 3 HFCS-sweetened beverages will contain 25% of energy requirement and the remainder of the provided diet will contain approximately 125% of energy requirement.
All the provided beverage will be consumed for eight weeks.
Only the provided beverage and diet will be consumed for eight weeks.
The provided diet will be consumed ad libitum and the uneaten portions will be returned to study staff.
|
High fructose corn syrup provided as 15% HFCS/85% water (weight/weight) fruit-flavored beverage
Other Names:
Provided in quantities that exceed energy requirement by approximately 25%.
Formulated such that the overall macronutrient intake; including beverage; equals approximately 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
Other Names:
|
Placebo Comparator: Asp-AL
Consume 3 servings/day of aspartame-sweetened beverage along with the provided ad libitum diet.
The 3 aspartame-sweetened beverages will contain 0% of energy requirement and the remainder of the provided diet will contain approximately 125% of energy requirement.
All the provided beverage will be consumed for eight weeks.
Only the provided beverage and diet will be consumed for eight weeks.
The provided diet will be consumed ad libitum and the uneaten portions will be returned to study staff.
|
Aspartame provided as 0.04% aspartame/99.96%
water (weight/weight), fruit-flavored beverage
Other Names:
Provided in quantities that exceed energy requirement by approximately 25%.
Formulated such that the overall macronutrient intake; including beverage; equals approximately 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of de novo lipogenesis: palmitate tracer-to-tracee ratios by gas chromatography-mass spectrometry.
Time Frame: 22 hours at Baseline and 4-week Intervention
|
Blood samples are collected during 26-h isotopic acetate infusion.
Blood samples are processed for determination of palmitate tracer-to-tracee ratios by gas chromatography-mass spectrometry.
|
22 hours at Baseline and 4-week Intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of endogenous glucose production measured by standard dilution techniques
Time Frame: 7 hours at Baseline and 4-week Intervention
|
Blood samples are collected during isotopic glucose infusion, and endogenous glucose production (glucose appearance) is measured by standard dilution techniques.
|
7 hours at Baseline and 4-week Intervention
|
Change of whole body insulin sensitivity
Time Frame: 3 hours at Baseline and 4-week Intervention
|
A variable 20% glucose infusion is adjusted to maintain euglycemia during insulin infusion in order to determine insulin-mediated glucose uptake.
|
3 hours at Baseline and 4-week Intervention
|
Change of liver lipid
Time Frame: Baseline, 4-week Intervention and 8-week intervention
|
Quantified from magnetic resonance imaging
|
Baseline, 4-week Intervention and 8-week intervention
|
Change of fat oxidation
Time Frame: 17 hours at Baseline and 4-week Intervention
|
Fat oxidation is calculated from measures of oxygen consumption and carbon dioxide production by indirect calorimetry.
|
17 hours at Baseline and 4-week Intervention
|
Change of Very low density lipoprotein (VLDL)-triglyceride (TG) kinetics
Time Frame: 22 hours at Baseline and 4-week Intervention
|
During overnight fasting VLDL-TG kinetics will be determined using a prime constant infusion of isotopic glycerol.
During the meal-feeding protocol, the washout kinetic enrichment of isotopic glycerol in the TG will be used to estimate VLDL-TG with a non-steady modeling approach.
|
22 hours at Baseline and 4-week Intervention
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of blood levels of LDL-cholesterol
Time Frame: Baseline and 4-week Intervention
|
fasting and postprandial plasma concentrations of TG, cholesterol, low density lipoprotein cholesterol, apolipoprotein B, apolipoprotein C3 are measured
|
Baseline and 4-week Intervention
|
Change of blood levels of non-HDL-cholesterol
Time Frame: Baseline and 4-week Intervention
|
fasting and postprandial plasma concentrations of TG, cholesterol, low density lipoprotein cholesterol, apolipoprotein B, apolipoprotein C3 are measured
|
Baseline and 4-week Intervention
|
Change of blood levels of apolipoprotein B
Time Frame: Baseline and 4-week Intervention
|
fasting and postprandial plasma concentrations of TG, cholesterol, low density lipoprotein cholesterol, apolipoprotein B, apolipoprotein C3 are measured
|
Baseline and 4-week Intervention
|
Change of blood levels of triglyceride
Time Frame: Baseline and 4-week Intervention
|
fasting and postprandial plasma concentrations of TG, cholesterol, low density lipoprotein cholesterol, apolipoprotein B, apolipoprotein C3 are measured
|
Baseline and 4-week Intervention
|
Change of blood levels of apolipoprotein C3
Time Frame: Baseline and 4-week Intervention
|
fasting and postprandial plasma concentrations of TG, cholesterol, low density lipoprotein cholesterol, apolipoprotein B, apolipoprotein C3 are measured
|
Baseline and 4-week Intervention
|
Change of blood levels of uric acid
Time Frame: Baseline and 4-week Intervention
|
fasting and postprandial plasma concentrations of uric acid are measured
|
Baseline and 4-week Intervention
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Peter J Havel, DVM, Ph.D, University of California, Davis
- Principal Investigator: Jean-Marc Schwarz, Ph.D., Touro University
- Study Director: Kimber L Stanhope, Ph.D., University of California, Davis
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Maersk M, Belza A, Stodkilde-Jorgensen H, Ringgaard S, Chabanova E, Thomsen H, Pedersen SB, Astrup A, Richelsen B. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study. Am J Clin Nutr. 2012 Feb;95(2):283-9. doi: 10.3945/ajcn.111.022533. Epub 2011 Dec 28.
- Bergwall S, Johansson A, Sonestedt E, Acosta S. High versus low-added sugar consumption for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2022 Jan 5;1(1):CD013320. doi: 10.1002/14651858.CD013320.pub2.
- Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, Hatcher B, Cox CL, Dyachenko A, Zhang W, McGahan JP, Seibert A, Krauss RM, Chiu S, Schaefer EJ, Ai M, Otokozawa S, Nakajima K, Nakano T, Beysen C, Hellerstein MK, Berglund L, Havel PJ. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest. 2009 May;119(5):1322-34. doi: 10.1172/JCI37385. Epub 2009 Apr 20.
- Stanhope KL, Schwarz JM, Havel PJ. Adverse metabolic effects of dietary fructose: results from the recent epidemiological, clinical, and mechanistic studies. Curr Opin Lipidol. 2013 Jun;24(3):198-206. doi: 10.1097/MOL.0b013e3283613bca.
- Cox CL, Stanhope KL, Schwarz JM, Graham JL, Hatcher B, Griffen SC, Bremer AA, Berglund L, McGahan JP, Keim NL, Havel PJ. Consumption of fructose- but not glucose-sweetened beverages for 10 weeks increases circulating concentrations of uric acid, retinol binding protein-4, and gamma-glutamyl transferase activity in overweight/obese humans. Nutr Metab (Lond). 2012 Jul 24;9(1):68. doi: 10.1186/1743-7075-9-68.
- Cox CL, Stanhope KL, Schwarz JM, Graham JL, Hatcher B, Griffen SC, Bremer AA, Berglund L, McGahan JP, Havel PJ, Keim NL. Consumption of fructose-sweetened beverages for 10 weeks reduces net fat oxidation and energy expenditure in overweight/obese men and women. Eur J Clin Nutr. 2012 Feb;66(2):201-8. doi: 10.1038/ejcn.2011.159. Epub 2011 Sep 28.
- Stanhope KL, Bremer AA, Medici V, Nakajima K, Ito Y, Nakano T, Chen G, Fong TH, Lee V, Menorca RI, Keim NL, Havel PJ. Consumption of fructose and high fructose corn syrup increase postprandial triglycerides, LDL-cholesterol, and apolipoprotein-B in young men and women. J Clin Endocrinol Metab. 2011 Oct;96(10):E1596-605. doi: 10.1210/jc.2011-1251. Epub 2011 Aug 17.
- Stanhope KL. Role of fructose-containing sugars in the epidemics of obesity and metabolic syndrome. Annu Rev Med. 2012;63:329-43. doi: 10.1146/annurev-med-042010-113026. Epub 2011 Oct 27.
- Aeberli I, Hochuli M, Gerber PA, Sze L, Murer SB, Tappy L, Spinas GA, Berneis K. Moderate amounts of fructose consumption impair insulin sensitivity in healthy young men: a randomized controlled trial. Diabetes Care. 2013 Jan;36(1):150-6. doi: 10.2337/dc12-0540. Epub 2012 Aug 28.
- Schwarz JM, Noworolski SM, Wen MJ, Dyachenko A, Prior JL, Weinberg ME, Herraiz LA, Tai VW, Bergeron N, Bersot TP, Rao MN, Schambelan M, Mulligan K. Effect of a High-Fructose Weight-Maintaining Diet on Lipogenesis and Liver Fat. J Clin Endocrinol Metab. 2015 Jun;100(6):2434-42. doi: 10.1210/jc.2014-3678. Epub 2015 Mar 31.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2016
Primary Completion (Actual)
March 13, 2020
Study Completion (Actual)
March 13, 2020
Study Registration Dates
First Submitted
May 26, 2015
First Submitted That Met QC Criteria
September 10, 2015
First Posted (Estimate)
September 14, 2015
Study Record Updates
Last Update Posted (Actual)
September 16, 2021
Last Update Submitted That Met QC Criteria
September 14, 2021
Last Verified
September 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 499106
- 1R01HL121324 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on high fructose corn syrup
-
Washington University School of MedicineCompleted
-
John SievenpiperCanadian Diabetes Association; The Physicians' Services Incorporated Foundation and other collaboratorsUnknownObesity | Overweight | Body Weight | Adiposity | Obesity, AbdominalCanada
-
University of TorontoCanadian Institutes of Health Research (CIHR); Canadian Diabetes Association; The Physicians' Services Incorporated FoundationUnknownCardiovascular Diseases | Stroke | Hypertension | Diabetes Mellitus, Type 2 | Gout | Metabolic Syndrome XCanada
-
Fred Hutchinson Cancer CenterNational Heart, Lung, and Blood Institute (NHLBI); University of WashingtonCompletedObesity | Cardiovascular Disease | Type 2 Diabetes Mellitus | Intestinal Permeability | Low-grade Chronic InflammationUnited States
-
University of TorontoCanadian Institutes of Health Research (CIHR); The Physicians' Services Incorporated... and other collaboratorsUnknownHypertension | Obesity | Cardiovascular Disease | Dyslipidemia | Prediabetes | Gout | Non-Alcoholic Fatty Liver Disease | DysglycemiaCanada
-
University of TorontoCanadian Diabetes Association; The Physicians' Services Incorporated Foundation and other collaboratorsUnknownHypertension | Cardiovascular Disease | Diabetes | Dyslipidemia | Non-alcoholic Fatty Liver Disease | Prediabetes | Gout | DysglycemiaCanada
-
University of TorontoCompletedAbdominal ObesityCanada
-
University of California, DavisNational Heart, Lung, and Blood Institute (NHLBI)CompletedMetabolic Syndrome | Insulin Resistance | DyslipidemiaUnited States
-
UCSF Benioff Children's Hospital OaklandAlmond Board of CaliforniaCompleted
-
USDA Grand Forks Human Nutrition Research CenterCompleted